CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION
Tissino, E; Caldana, C; Benedetti, D; Herman, SE; ten Hacken, E; Rossi, FM; Dal Bo, M; Bulian, P; Bomben, R; Zaja, F; Chiarenza, A; Sklar, LA; Hartmann, TN; Chigaev, A; Burger, JA; Del Poeta, G; Wiestner, A; Gattei, V; Zucchetto, A HAEMATOLOGICA. 2016; 101: 49-50.
CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Hinterseer, E; Hutterer, E; Krenn, PW; Reinthaler, P; Hopner, J; Hopfinger, M; Eulberg, D; Maasch, C; Kruschinski, A; Vater, A; Egle, A; Greil, R; Hartmann, TN HAEMATOLOGICA. 2016; 101: 45-46.
Blocking CD62L inhibits CLL cell interaction with vascular endothelium; an effect that is augmented by ibrutinib
Shere, C; Hartmann, TN; Pratt, G; Fegan, C; Pepper, C; Walsby, EJ BRIT J HAEMATOL. 2016; 173: 7-8.
Tumor response as important parameter during first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
Karthaus, M; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Zhang, Y; Demonty, G; Kohne, CH ONCOL RES TREAT. 2016; 39: 73-73.
A CXCR4 inhibitor and Btk inhibitor ONO/GS-4059 are synergistic and result in loss of CLL cell migratory ability and survival
Lewis, T; Proctor, VK; Brennan, P; Pratt, G; Hartmann, TN; Buggins, AGS; Yoshizawa, T; Fegan, C; Pepper, C; Walsby, EJ BRIT J HAEMATOL. 2016; 173: 8-8.
DNA methylation patterns correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer
Gampenrieder, SP; Rinnerthaler, G; Weinhausel, A; Pulverer, W; Hugnagl, C; Hackl, H; Romeder, F; Fuentes, CM; Hauser-Kronberger, C; Mlineritsch, B; Greil, R CANCER RES. 2016; 76:
Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
Singer, CF; Filipits, M; Jahn, S; Abete, L; Jakesz, R; Greil, R; Bauernhofer, T; Kwasny, W; Seifert, M; Fitzal, F; Schmitt, M; Moinfar, F; Gnant, M CANCER RES. 2016; 76:
Kollagenosen
Psenak, O; Fortbildungsseminar für Turnusärzte SALK; 19.07.2016; Salzburg. 2016.
Differentialdiagnose der Gelenksentzündungen, Kollagenosen
Psenak, O; PMU-Lehre für 3. Jahrgang:_x000D_ Pathophysiologische des muskuloskelettalen Apparates; 23.08.2016; Salzburg. 2016.
CDK4/6: Intranukleäre vs. zytoplasmische Inhibition
Gampenrieder, SP; Onkologische Wintergespräche; 15.01.2016; Wien. 2016.
